SearcharxivSearch

arXiv subjects

Max Sunog

Publications and source records attributed to Max Sunog.

2 recordsLinked to original sources

Reflections from Research Roundtables at the Conference on Health, Inference, and Learning (CHIL) 2025

The 6th Annual Conference on Health, Inference, and Learning (CHIL 2025), hosted by the Association for Health Learning and Inference (AHLI), was held in person on June 25-27, 2025, at the University of California, Berkeley, in Berkeley, California, USA. As part of this year's program, we hosted Research Roundtables to catalyze collaborative, small-group dialogue around critical, timely topics at the intersection of machine learning and healthcare. Each roundtable was moderated by a team of senior and junior chairs who fostered open exchange, intellectual curiosity, and inclusive engagement. The sessions emphasized rigorous discussion of key challenges, exploration of emerging opportunities, and collective ideation toward actionable directions in the field. In total, eight roundtables were held by 19 roundtable chairs on topics of "Explainability, Interpretability, and Transparency," "Uncertainty, Bias, and Fairness," "Causality," "Domain Adaptation," "Foundation Models," "Learning from Small Medical Data," "Multimodal Methods," and "Scalable, Translational Healthcare Solutions."

cs.LG

Investigating Primary Care Indications to Improve Electronic Health Record in Dementia Target Trial Emulation

Missing data, inaccuracies in medication lists, and recording delays in electronic health records (EHR) are major limitations for target trial emulation (TTE), the process by which EHR data are used to retrospectively emulate a randomized control trial. EHR TTE relies on recorded data that proxy true drug exposures and outcomes. We investigate the under-utilized criterion that a patient has indications of primary care provider (PCP) encounters within the EHR. Such patients tend to have more records overall and a greater proportion of the types of encounters that materialize comprehensive and up-to-date records. We examine the impact of including a PCP feature in the TTE model or as an eligibility criterion for cohort selection, contrasted with ignoring it altogether. To that end, we compare the estimated effects of two first line antidiabetic drug classes on the onset of Alzheimer's Disease and Related Dementias (ADRD). We find that the estimated treatment effect is sensitive to the consideration of a PCP feature, particularly when used as an eligibility criterion. Our work suggests that this PCP feature should be further researched.

stat.AP